Welcome to our dedicated page for Harmony Biosciences Holdings SEC filings (Ticker: HRMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. Harmony Biosciences is a commercial-stage pharmaceutical company focused on rare neurological diseases, and its filings offer detailed insight into financial performance, clinical milestones and strategic developments around its WAKIX (pitolisant) franchise and late-stage CNS pipeline.
Recent Forms 8-K filed by Harmony Biosciences report preliminary and actual financial results, such as net product revenue for WAKIX, multi-quarter revenue growth and updated annual guidance ranges. These filings also incorporate press releases and investor presentations that describe the company’s status as a profitable, self-funding biotech with a robust late-stage pipeline, as well as disclosures tied to participation in major healthcare conferences. For investors analyzing HRMY, these documents help contextualize revenue trends, cash generation and spending on research and development, sales and marketing, and general and administrative activities.
Harmony’s 8-K filings also reference significant clinical and regulatory events, including topline data from the Phase 3 RECONNECT study of ZYN002 in Fragile X syndrome, preannounced WAKIX performance, and updates on Phase 3 and Phase 1 programs such as pitolisant GR, pitolisant HD, EPX-100, EPX-200 and BP1.15205. Through these filings, readers can follow how clinical outcomes, trial initiations and program decisions feed into the company’s overall strategy in sleep–wake disorders, rare epilepsies and neurobehavioral conditions.
On Stock Titan, Harmony Biosciences’ SEC filings are complemented by AI-powered summaries that explain the key points of lengthy documents, including 8-Ks and, when available, 10-K annual reports, 10-Q quarterly reports and proxy materials. Investors can also monitor insider and executive transaction reports on Form 4 and other ownership filings as they appear in the EDGAR feed. This combination of real-time updates and AI-generated explanations helps users quickly understand the implications of HRMY’s regulatory disclosures without reading every page of each filing.
Harmony Biosciences Holdings, Inc. filed a current report describing a new press release with preliminary, unaudited net product revenue for the fourth quarter and full year ended December 31, 2025. The release also includes the company’s guidance for 2026 net product revenue and an update on its clinical programs.
The company will present at the 44th Annual JP Morgan Healthcare Conference on January 13, 2026, and the related presentation is attached to the report. The materials, including the press release and slideshow, are being furnished rather than filed, and the company highlights that they contain forward-looking statements subject to risks and uncertainties described in its prior SEC reports.
Harmony Biosciences Holdings, Inc. reported an insider transaction by its president, CEO and director on a Form 4. On 12/12/2025, the executive exercised a stock option for 20,000 shares of common stock at an exercise price of $8.22 per share, converting the option into shares.
That same day, the executive sold 20,000 shares and an additional 5,933 shares of common stock in open-market transactions under a Rule 10b5-1 trading plan. The reported weighted average sale price was $40.1073 per share, with individual trades occurring between $40.00 and $40.28. Following these transactions, the Form 4 reports 0 shares of common stock and 0 derivative securities beneficially owned directly from this option grant.
Harmony Biosciences Holdings, Inc. (HRMY) reported an insider stock sale by its chief financial officer. On 11/21/2025, the CFO sold 3,427 shares of common stock at a price of $35 per share, coded as an open market or similar sale (transaction code "S").
After this transaction, the reporting person disclosed beneficial ownership of 0 shares, held directly. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan, which is designed to allow insiders to sell shares according to predetermined instructions.
Harmony Biosciences (HRMY) reported strong Q3 2025 results. Net product revenue reached $239,455, generating gross profit of $179,805 and operating income of $65,487. Net income was $50,865, with diluted EPS of $0.87 on 58,717,910 weighted-average diluted shares.
R&D expense rose to $54,962 as the company advanced programs, while sales and marketing and G&A were $29,549 and $29,807, respectively. Cash and cash equivalents were $646,999, and total cash, cash equivalents and investments were $778,412 as of September 30, 2025. Long-term debt principal stood at $170,000 with a 2028 maturity schedule. The company triggered a $15,000 CVR payment tied to a Zynerba milestone, payable in Q4 2025. As of October 31, 2025, 57,596,358 common shares were outstanding. The ANDA settlements allow licensed generic entry beginning January 2030, or earlier under certain circumstances.
Harmony Biosciences (HRMY) filed an 8-K announcing it furnished a press release with financial results for the quarter ended September 30, 2025 and posted an updated investor presentation. The materials are included as Exhibits 99.1 and 99.2 and are provided under Regulation FD.
The company states these exhibits are furnished and not deemed filed under Section 18 of the Exchange Act, and may be used in presentations to investors and analysts. Forward‑looking statements are subject to the risk factors described in prior SEC filings.
Harmony Biosciences (HRMY) announced preliminary net product revenue for the third quarter of 2025 and updated its 2025 net product revenue guidance. The company furnished these details in a press release attached as Exhibit 99.1.
The disclosure falls under Results of Operations and Financial Condition and includes standard forward‑looking statement language.
Sandip Kapadia, Chief Financial Officer of Harmony Biosciences Holdings, Inc. (HRMY), reported transactions dated 09/30/2025. He acquired 45,000 shares upon vesting of restricted stock units (RSUs) granted on 10/04/2023, and a portion of those shares were withheld to satisfy income tax withholdings as noted. Separately, he disposed of 24,039 shares at a price of $27.56 per share, leaving him with 20,961 shares beneficially owned after the sale. The RSUs vest on a schedule: 40% vested on 09/30/2024, and 30% vest on each of 09/30/2025 and 09/30/2026. The filing was signed by an attorney-in-fact on 10/02/2025.
Harmony Biosciences Holdings, Inc. reported new clinical data from its phase 3 registrational RECONNECT study. The company announced topline results showing that the trial did not meet its primary endpoint, which was based on improvement in social avoidance. According to the company, this outcome was primarily due to a higher than expected placebo response rate, which reduced the measured difference between treatment and placebo groups.
The company furnished a detailed press release with the topline results as an exhibit to this report. The disclosure is provided under Regulation FD, meaning Harmony is sharing this information broadly with the market at the same time.
Harmony Biosciences (HRMY) Form 4: Valor IV Pharma Holdings, LLC reported an in-kind pro rata distribution on 08/28/2025 that disposed of 6,618,033 shares of Harmony common stock without consideration, leaving 0 shares directly owned by Valor IV Pharma Holdings following that transaction. The filing lists remaining indirect holdings across related Valor entities and individuals totaling specific lots of 29,497, 437,619, 50,423, 38,275 and 23,714 shares, held by Valor Management L.P., Antonio Gracias, AJG Growth Fund LLC, Juan Sabater and Tamal, LLC, respectively. The distribution is described in footnotes as an in-kind pro rata distribution by Valor IV Pharma Holdings, LLC, without consideration. The filing is signed by Valor principals and by directors Antonio Gracias and Juan A. Sabater on 09/02/2025.
Sandip Kapadia, Chief Financial Officer of Harmony Biosciences Holdings, Inc. (HRMY), sold 21,573 shares of the company's common stock on 08/15/2025 under a Rule 10b5-1 trading plan. The transactions were executed at a weighted average price of $36.4983 per share, with individual sale prices ranging from $36.11 to $36.87. After these dispositions, the Form 4 reports 0 shares beneficially owned by the reporting person. The filing notes the sale was made pursuant to an established trading plan and offers to provide, upon request, the number of shares sold at each price within the disclosed range.